Eli Lilly Announces Promising Weight Loss Drug Combination
Eli Lilly (LLY) has announced positive results from its phase 2 trial of EloraTZP, a combination therapy that outperformed tirzepatide alone in weight loss for patients with type 2 diabetes and obesity. The drug combines tirzepatide with eloralintide to target three hormonal pathways involved in appetite control and blood sugar regulation. EloraTZP achieved an average of 23.3% weight loss compared to 14.8% from tirzepatide alone, positioning it as a potential blockbuster drug for the company's already dominant GLP-1 portfolio that includes Mounjaro and Zepbound. The phase 3 trials are set to begin in Q4. Lilly currently holds about 60% of the U.S. market for these drugs and is competing with Novo Nordisk, which was first to launch a successful GLP-1 drug. Analysts predict this sector could reach $100 billion by decade's end.
Tickers: $LLY
Topics: Eli Lilly Foundayo GLP-1 drugs Mounjaro weight loss medications Zepbound